Superficial bladder tumours: Analysis of prognostic factors and construction of a predictive index

BJU International

Volumn 92, Issue 4, 2003, Pages 393-399

  Ali El Dein, B ^a   Sarhan, O ^a   Hinev, A ^b   Ibrahiem, El H I ^a   Nabeeh, A ^a   Ghoneim, M A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

Author keywords

Multivariate analysis; Predictive index; Progression; Recurrence; Superficial bladder tumour

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RECURRENT DISEASE; REGRESSION ANALYSIS; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; VALIDATION PROCESS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0042411205     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04360.x     Document Type: Article

References (34)

1. Soloway MS. The management of superficial bladder cancer. Cancer 1980; 45: 1856-65
2. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer. progression and recurrence. J Urol 1983; 130: 1083-6
3. Ali-El-Dein B, El-Baz M, Nabeeh A, Shamaa S, Ashamallah A. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 1997; 158: 68-74
4. Heney NM. Natural history of superficial bladder cancer: Prognostic features and long-term disease course. Urol Clin North Am 1992; 19: 429-33
5. Fitzpatrick JM, West AB, Butler MR et al. Superficial bladder tumors (stages pTa, grades 1 and 2). The importance of recurrence pattern following initial resection. J Urol 1986; 135: 920-2
6. Ali-El-Dein B, Nabeeh A, Ismail E et al. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol 1999; 162: 339-42
7. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73-8
8. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 475-81
9. Peto R, Peto J. Asymptotically efficient rank in variant procedures. J R Stat Soc Series A 1972; 135: 185-207
10. Cox DR. Regression models and life tables. J R Stat Soc Series B 1972; 34: 187
11. Feldman AR, Kessler L, Myer M et al. The prevalence of cancer. Estimates based on Connecticut Tumor Registry. New Engl J Med 1986; 315: 1394-6
12. Herr HW, Laudone VP, Whitmore WF et al. An overview of intravesical therapy for superficial bladder tumors. J Urol 1987; 138: 1363-8
13. Kurth KH, Sylvester R, de Pauw M et al. Intracavitary treatment of transitional cell carcinoma of the bladder: questions and lessons after 27 years of experience. In Debruyne FMJ, Denis L, van der Meyden AMP eds, EORTC Genitourinary Group Monograph 6: BCG in Superficial Bladder Cancer. New York: Alan R. Liss, 1989: 125-45
14. Dalesio O, Schulman CC, Sylvester R et al. Prognostic factors in superficial bladder tumors. A study of the European Organisation for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 1983; 129: 730-3
15. Herr HW, Badalament RA, Amato DA et al. Superficial bladder cancer treated with bacillus Calmette-Guerin. A multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 22-9
16. Parmar MKB, Freedman LS, Hargreave TB et al. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on superficial bladder cancer (Urological Cancer Working Party). J Urol 1989; 142: 284-8
17. Mulders PFA, van der Meyden APM, Doesburg WH et al. Prognostic factors in pTa-pT1 superficial bladder tumors treated with intravesical instillations. Br J Urol 1994; 73: 403-8
18. Sato N, Sumiya H, Isaka S et al. Prognostic factors for progression of superficial bladder cancer. Jap J Urol 1992; 83: 1263-9
19. Chopin DK, Popov Z, Ravery V et al. Prognostic factors in superficial bladder cancer. World J Urol 1993; 11: 148-52
20. Fitzpatrick JM. Superficial bladder carcinoma. Factors affecting the natural history. World J Urol 1993; 11: 142-7
21. Reading J, Hall RR, Parmar MKB. The application of a prognostic factor analysis for Ta. T1 bladder cancer in routine urological practice. Br J Urol 1995; 75: 604-7
22. Allard P, Bernard P, Yradet Y et al. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692-8
23. Hemstreet GP III, Rollins S, Jones P et al. Identification of a high risk subgroup of grade 1 transitional cell carcinoma using image analysis based deoxyribonucleic acid ploidy analysis of tumor tissue. J Urol 1991; 146: 1525-9
24. van Velthoven R, Petein M, Oosterlinck WJ et al. The use of digital image analysis of chromatin texture in Feulgen-stained nuclei to predict recurrence of low grade superficial transitional cell carcinoma of the bladder. Cancer 1995; 75: 560-8
25. Stein JP, Grossfeld GD, Ginsberg DA et al. Prognostic markers in bladder cancer. a contemporary review of the literature. J Urol 1998; 160: 645-59
26. Ghoneim MA, El-Mekresh MM, Mokhtar AA et al. A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 2000; 85: 811-6
27. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 1997; 12: 488-94
28. Witjes JA, Kiemeney LALM, Verbeek AL et al. Random bladder biopsies and the risk of recurrent superficial bladder cancer: a prospective study in 1026 patients. World J Urol 1992; 10: 231-4
29. Kiemeney LALM, Witjes JA, Heijbroek RP et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 60-4
30. Skinka T, Matsumoto M, Ogura H et al. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guerin: a long-term followup. Int J Urol 1997; 4: 139
31. Gustafson H, Tribukait B. Characterization of bladder carcinoma by flow DNA analysis. Eur Urol 1985; 11: 410-7
32. Blomjous ECM, Schipper NW, Baak JPA et al. The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. Am J Clin Path 1989; 91: 243-8
33. Solsona E, Iborra I, Dumont R et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; 164: 685-9
34. Hinev AI, Diacov C. Computer assisted metaphylaxis of superficial bladder tumors. J BUON 1996; 1: 11